Industry calls for greater competitiveness incentives in EU Biotech Act
· nuala moran
AI Briefing
- • EU Biotech industry supports the EU Biotech Act but calls for greater competitiveness incentives.
- • Industry advocates for wide-ranging changes to support the full lifecycle of drug development.
- • Competitiveness incentives are needed to restore Europe's position in the biopharma industry.
Context
The industry is supporting the EU Biotech Act, but believes it does not go far enough. Companies want to see wide-ranging change that will support the full lifecycle of drug development, including academic research and commercialization.
The proposed changes matter because they would help restore Europe's competitive position in biopharma, according to the industry. A system that fully supports drug development is needed to achieve this goal.
Advertisement